About ContraFect (NASDAQ:CFRXU)
ContraFect Corporation (ContraFect ) is a biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. It intends to address drug-resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. CF-301 and CF-302 are bacteriophage lysins with potent activity against Staph aureus infections.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-4.81102362204724
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
ContraFect (NASDAQ:CFRXU) Frequently Asked Questions
What is ContraFect's stock symbol?
ContraFect trades on the NASDAQ under the ticker symbol "CFRXU."
Who are some of ContraFect's key competitors?
Some companies that are related to ContraFect include Galectin Therapeutics (GALT), Nabriva Therapeutics (NBRV), Corvus Pharmaceuticals (CRVS), Pluristem Therapeutics (PSTI), Palatin Technologies (PTN), Eiger Biopharmaceuticals (EIGR), Zynerba Pharmaceuticals (ZYNE), ArQule (ARQL), Sunesis Pharmaceuticals (SNSS), Organovo (ONVO), CTI BioPharma (CTIC), Merrimack Pharmaceuticals (MACK), Compugen (CGEN), Silence Therapeutics (SLN), Asterias Biotherapeutics (AST), Regulus Therapeutics (RGLS), Curis (CRIS) and Oramed Pharmaceuticals (ORMP).
Who are ContraFect's key executives?
ContraFect's management team includes the folowing people:
- Steven C. Gilman Ph.D., Chairman of the Board, Chief Executive Officer (Age 64)
- Joshua B. Muntner, Co-Chief Executive Officer, Senior Vice President - Business Development (Age 48)
- Michael Messinger CPA, Co-Chief Executive Officer, Vice President - Finance (Age 42)
- Roger Pomerantz M.D., Vice Chairman of the Board (Age 60)
- Nancy Dong, Vice President, Controller
- Cara M. Cassino M.D., General Counsel, Secretary, Chief Medical Officer (Age 55)
- Natalie Bogdanos, General Counsel and Corporate secratary (Age 46)
- Sol J. Barer Ph.D., Lead Independent Director (Age 69)
- Lisa R. Ricciardi, Director (Age 56)
- Isaac Blech, Independent Director (Age 67)
How do I buy ContraFect stock?
Shares of ContraFect can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ContraFect's stock price today?
One share of ContraFect stock can currently be purchased for approximately $6.11.
How big of a company is ContraFect?
ContraFect has a market capitalization of $117.86 million.
How can I contact ContraFect?
ContraFect's mailing address is 28 Wells Ave Ste 3, YONKERS, NY 10701-7045, United States. The biotechnology company can be reached via phone at +1-914-2072300.
MarketBeat Community Rating for ContraFect (CFRXU)MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
ContraFect (NASDAQ:CFRXU) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for ContraFect (NASDAQ:CFRXU)
No earnings announcements for this company have been tracked by MarketBeat.com
ContraFect (NASDAQ:CFRXU) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ContraFect (NASDAQ:CFRXU)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ContraFect (NASDAQ CFRXU)
No insider trades for this company have been tracked by MarketBeat.com
ContraFect (NASDAQ CFRXU) News Headlines
ContraFect (NASDAQ:CFRXU) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
ContraFect (NASDAQ CFRXU) Stock Chart for Tuesday, January, 16, 2018